Takeda Accused In U.S. Court Suit Hiding Actos Cancer Risk For Years
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical was accused at the end of the first of more than 3,000 U.S. court trials of hiding the risks of bladder cancer associated with its Actos (pioglitazone) diabetes drug.